Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

187
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
187
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

164
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
164
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

147
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
147
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

123
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
123
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

168
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
168
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

88
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
88

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secondary Anticoagulation Prophylaxis for Children with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis.

Blood advances·2026
Same author

Transfusion of blood products to neonatal and pediatric extracorporeal membrane oxygenation patients: A prospective, observational study.

Transfusion·2026
Same author

Treatment and outcomes of thromboembolism in paediatric patients with cardiac disease in a cardiac ICU: a single-centre retrospective study.

Cardiology in the young·2026
Same author

Reference intervals for haptoglobin in neonates and children 30 days to 18 years old.

Scandinavian journal of clinical and laboratory investigation·2026
Same author

Contemporary management of pediatric venous thrombosis: how does it differ from adult care?

Journal of thrombosis and haemostasis : JTH·2026
Same author

The <i>in vitro</i> anticoagulant effect of abelacimab in healthy children.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Video

Updated: Dec 18, 2025

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine
06:09

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine

Published on: January 12, 2024

938

Paediatric Reference Intervals: Current Status, Gaps, Challenges and Future Considerations.

Monsurul Hoq1,2,3, Susan Matthews4, Susan Donath1,3

  • 1Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, Vic. 3052, Australia.

The Clinical Biochemist. Reviews
|June 11, 2020
PubMed
Summary
This summary is machine-generated.

Establishing pediatric reference intervals (RIs) is difficult but feasible. Future work must address gaps in applying these RIs in routine practice and harmonizing results across different lab analyzers.

More Related Videos

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

27.6K
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K

Related Experiment Videos

Last Updated: Dec 18, 2025

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine
06:09

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine

Published on: January 12, 2024

938
Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

27.6K
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K

Area of Science:

  • Clinical Biochemistry
  • Laboratory Medicine
  • Paediatric Diagnostics

Background:

  • Establishing paediatric reference intervals (RIs) faces challenges like recruitment, blood volume, and age-related physiological changes.
  • Previous initiatives show feasibility of prospective paediatric RI studies, continuous RIs, and harmonisation across analysers.

Purpose of the Study:

  • To review progress in paediatric RI studies and identify remaining gaps for routine laboratory practice.
  • To outline future priorities for paediatric RI research and implementation.

Main Methods:

  • Review of national and international initiatives in paediatric RI studies.
  • Analysis of challenges in translating paediatric RIs into clinical practice.

Main Results:

  • Paediatric RI studies are feasible and have led to continuous RIs and harmonised values.
  • Gaps remain in applying RIs, understanding clinical implications of analyser variation, and adapting lab systems.

Conclusions:

  • Future priorities include evaluating RI types, clinical impact of variations, system adaptation, and neonatal data.
  • Further research and collaboration are needed for robust, clinically fit-for-purpose paediatric RIs.